Abstract
Exclusion of the older population from clinical trials has for long resulted in a knowledge gap about drug efficacy and side effects in older age groups. When considering the demographic change in most industrialized countries and the fact that seniors receive the highest share of all drugs, a need for clinical trials with elderly patients is obvious. Potential pharmacokinetic as well as pharmacodynamic changes in comparison to younger adults have to be described. The safety profile can be different due to several reasons, which may be explained by comorbidities, comedications, or age-related changes. Calendar age serves only as a proxy for age, and geriatric assessment tools should more and more be applied to characterize the heterogenous group of older adults from 65 years to more than 100 years of age. Several ICH guidelines and reflection papers from regulatory bodies do exist and offer advice on how to design and analyze clinical trials including the older population.
References and Further Reading
Baijens LW, Clavé P, Cras P et al (2016) European Society for Swallowing Disorders – European Union Geriatric Medicine Society white paper: oropharyngeal dysphagia as a geriatric syndrome. Clin Interv Aging 11:1403–1428
Bartlam B, Crome P, Lally F et al (2012) The views of older people and carers on participation in clinical trials. Clin Invest 2:327–336
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel (2019) American Geriatrics Society 2019 Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 67:674–694
Cerreta F, Temple R, Asahin C et al (2015) Regulatory activities to address the needs of older patients. J Nutr Health Aging 19:232–233
Cerreta F, Ankri J, Bowen D et al (2016) Baseline frailty evaluation in drug development. J Frailty Aging 5:139–140
Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al (2010) Sarcopenia: European consensus on definition and diagnosis. Age Ageing 39:412–423
da Costa JP, Vitorino R, Silva GM et al (2016) A synopsis on aging – theories, mechanisms and future prospects. Ageing Res Rev 29:90–112
Doherty TJ (2003) invited review: aging and sarcopenia. J Appl Physiol 95:1717–1727
Downing NS, Shah ND, Neiman JH et al (2016) Participation of the elderly, women, and minorities in pivotal trials supporting 2011– 2013 U.S. Food and Drug Administration approvals. Trials 17:199. https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-016-1322-4. Accessed 26 May 2019
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) (2018) Reflection paper on physical frailty: instruments for baseline characterisation of older populations in clinical trials. EMA/CHMP/778709/2015. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-physical-frailty-instruments-baseline-characterisation-older-populations-clinical_en.pdf. Accessed 26 May 2019
Formiga F, Ferrer A, Padros G et al (2016) Evidence of functional declining and global comorbidity measured at baseline proved to be the strongest predictors for long-term death in elderly community residents aged 85 years: a 5-year follow-up evaluation, the OCTABAIX study. Clin Interv Aging 11:437–444
Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–M156
GBD Mortality Collaborators (2018a) Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1684–1735
GBD Mortality Collaborators (2018b) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1789–1858
Guigoz Y, Lauque S, Vellas BJ (2002) Identifying the elderly at risk for malnutrition. The Mini Nutritional Assessment. Clin Geriatr Med 18:737–757
Guralnik JM, Simonsick EM, Ferrucci L et al (1994) A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 49:M85–M94
Hilmer SN, Mager DE, Simonsick EM et al (2007) A drug burden index to define the functional burden of medications in older people. Arch Intern Med 167:781–787
Inouye SK, Studenski S, Tinetti ME, Kuchel GA (2007) Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc 55:780–791
International Conference on Harmonisation of Technical requirements for Registration of Pharmaceuticals for Human Use (1993) ICH Harmonised Tripartite Guideline. Studies in Support of Special Populations: Geriatrics E7.Current Step 4 Version. CPMP/ICH/379/95. https://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html. Accessed 26 May 2019
International Conference on Harmonisation of Technical requirements for Registration of Pharmaceuticals for Human Use (2010) E 7 Questions and Answers. EMA/CHMP/ICH/604661/2009. https://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html. Accessed 26 May 2019
Johnston C, Hilmer SN, McLachlan AJ et al (2014) The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration. Eur J Clin Pharmacol 70:549–555
Lewis JH, Kilgore ML, Goldman DP et al (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383–1389
Mangoni AA, Pilotto A (2016) New drugs and patient-centred end-points in old age: setting the wheels in motion. Expert Rev Clin Pharmacol 9:81–89
Melgaard D, Rodrigo-Domingo M, Mørch MM (2018) The prevalence of oropharyngeal dysphagia in acute geriatric patients. Geriatrics 26(15). https://doi.org/10.3390/geriatrics3020015.
Miller MD, Paradis CF, Houck PR et al (1992) Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 41:237–248
Nasreddine ZS, Phillips NA, Bédirian V et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699
Notenboom K, Leufkens HG, Vromans H, Bouvy ML (2017) Learning from patients: Identifying design features of medicines that cause medication use problems. Int J Pharm 517:128–134
O’Reilly A, Murphy J, Rawe S, Garvey M (2018) Chronic lymphocytic leukemia: a review of front-line treatment options, with a focus on elderly CLL patients. Clin Lymphoma Myeloma Leuk 18:249–256
Qato DM, Wilder J, Schumm PL et al (2016) Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med 176:473–482
Reeve E, Wiese MD, Mangoni AA (2015) Alterations in drug disposition in older adults. Expert Opin Drug Metab Toxicol 11:491–508
Renom-Guiteras A, Meyer G, Thürmann PA (2015) The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol 71:861–875
Schlender JF, Meyer M, Thelen K et al (2016) Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals. Clin Pharmacokinet 55:1573–1589
Schwartz JB, Verotta D (2009) Population analyses of atorvastatin clearance in patients living in the community and in nursing homes. Clin Pharmacol Ther 86:497–502
Shah RR (2004) Drug development and use in the elderly: search for the right dose and dosing regimen. Br J Clin Pharmacol 58:452–469
Soto-Perez-de-Celis E, Li D, Yuan Y (2018) Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol 19:e305–e316
Strehler BL (1962) Time, cells, and aging. Academic, New York
Tan JL, Eastment JG, Poudel A, Hubbard RE (2015) Age-related changes in hepatic function: an update on implications for drug therapy. Drugs Aging 32:999–1008
Thompson CM, Johns DO, Sonawane B et al (2009) Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly. J Toxicol Environ Health B Crit Rev 12:1–24
van den Akker M, Buntinx F, Knottnerus JA (2009) Comorbidity or multimorbidity. Eur J Gen Pract 2:65–70
Van Deudekom FJ, Postmus I, Van der Ham DJ et al (2017) External validity of randomized controlled trials in older adults, a systematic review. PLoS ONE 12(3):e0174053
van Riet-Nales DA, Hussain N, Sundberg KA et al (2016) Regulatory incentives to ensure better medicines for older people: from ICH E7 to the EMA reflection paper on quality aspects. Int J Pharm 512:343–351
Vitale C, Fini M, Spoletini I et al (2017) Under-representation of elderly and women in clinical trials. Int J Cardiol 232:216–221
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this entry
Cite this entry
Thürmann, P.A. (2019). Clinical Studies in Geriatric Population. In: Hock, F., Gralinski, M. (eds) Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-319-56637-5_43-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56637-5_43-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56637-5
Online ISBN: 978-3-319-56637-5
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences